The U.S. Food and Drug Administration has granted approval for a generic version of allopurinol, submitted under ANDA 077353. The product is manufactured by Chartwell RX, LLC and will be marketed as prescription tablets.
The approved dosage forms are oral tablets containing 100 mg and 300 mg of allopurinol. Both strengths are listed under the brand name “ALLOPURINOL” with product numbers 001 and 002. The FDA submission history includes an original approval on September 8 2005 and labeling supplements filed on March 19 2019 and March 19 2025.
Regulatorische Updates25. Sept. 2026•1 Min. Lesezeit
FDA Approves Chartwell Allopurinol Generic (ANDA077353)
FDA has approved Chartwell RX's generic allopurinol tablets (100 mg and 300 mg) under ANDA 077353, confirming prescription status and labeling updates.
Zusammengestellt vom PharmaCountry-Team · Quelle: FDA.gov
Bewertungen
(0)
(0)
(0)
(0)
(0)
Weitere Artikel
Alle Einblicke anzeigenStudien & Berichte
Global Finished Dosage Manufacturing Landscape 2026
5. Okt. 2026
Regulatorische UpdatesKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
28. Sept. 2026
AnalysePharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
28. Sept. 2026
Bewertung hinterlassen